Monday, May 29, 2006

Biotech News - Rosetta Biosoftware Announces the Rosetta Syllego System for Genetic Data Manage

------------------------ Yahoo! Groups Sponsor --------------------~-->
Home is just a click away.  Make Yahoo! your home page now.

Rosetta Biosoftware Announces the Rosetta Syllego System for Genetic
Data Management and Analysis

New Product to be Showcased at Workshop at
11 th Annual Human Genome Meeting in Helsinki , Finland

SEATTLE, Wash., May 19, 2006– Rosetta Biosoftware announced today
the availability of their new product, the Rosetta Syllego™ Genetic
Data Management and Analysis System for genetic studies. The system
is designed to effectively manage genetic data from disparate
sources and combine relevant genotypic and phenotypic study data so
that scientists can spend their time analyzing data and drawing
conclusions instead of contending with data from multiple sources.

"Customers and prospects have shared with us their frustrations for
finding a resource that can capture and store data from a range of
sources, so we designed the Syllego system to address this need. The
system enables researchers to plan and conduct genetic studies using
various commercial genotyping platforms and vendor assays and
integrate relevant study data," said Yelena Shevelenko, vice
president and general manager of Rosetta Biosoftware. "Further, the
system includes quality control tools to prevent loss of time in
downstream analyses as well as automation and project management
tools to record and plan analysis workflows and catalog data for
future studies. All of these tools help scientists spend less time
transforming and formatting data and more time analyzing data."

The Syllego system also includes basic data analysis tools and the
ability to integrate study data with common statistical packages,
such as R. The system will be demonstrated at the Human Genome
Organisation conference in Helsinki, Finland, May 31 - June 3, as
well at Rosetta Biosoftware's upcoming conference, the Rosetta
Technology Forum, also in Helsinki, June 4 - 5. To register for this
forum free of charge, please visit

About the Rosetta Syllego System

The Rosetta Syllego system is Rosetta Biosoftware's practical
solution for genetic data management and analysis. Designed for
scientists engaged in genetic studies, such as eQTL or genome-wide
association or linkage, the system is a resource for managing
genetic variation information. The system captures and stores SNP
genotyping assay data and information from leading technology
platforms so that you can better plan and execute genetic studies.
QC tools help you verify that data are high-quality to prevent loss
of time in downstream analyses. Application tools enable you to
combine relevant genotypic and phenotypic study data to interface
with the statistical environment of your choice. And automation
tools enable you to analyze and catalog study data and analysis
results, so that you can incorporate findings into future studies.
Because the system is built upon Rosetta Biosoftware's existing
informatics platform, it can integrate with other Rosetta
Biosoftware products, your own in-house tools, or other third-party
platforms. For more information on the Syllego system, please visit

About Rosetta Biosoftware

Rosetta Biosoftware is a leading provider of informatics solutions
for life science research. Its comprehensive software solutions,
including the Rosetta Resolver, Rosetta Elucidator, and Rosetta
Syllego systems, empower life scientists with advanced, scalable,
and easy-to-use analysis platforms that accelerate discovery
research. Rosetta Biosoftware is a business unit of Rosetta
Inpharmatics LLC, a wholly owned subsidiary of Merck & Co., Inc.
(NYSE: MRK). More information about Rosetta Biosoftware is available

Forward-Looking Statements

This press release contains "forward-looking statements" as that
term is defined in the Private Securities Litigation Reform Act of
1995. These statements involve risks and uncertainties, which may
cause results to differ materially from those set forth in the
statements. The forward-looking statements may include statements
regarding product development, product potential, or financial
performance. No forward-looking statement can be guaranteed, and
actual results may differ materially from those projected. Neither
Rosetta Inpharmatics nor Merck & Co., Inc. undertakes any obligation
to publicly update any forward-looking statement, whether as a
result of new information, future events, or otherwise. Forward-
looking statements in this press release should be evaluated
together with the many uncertainties that affect the business of
Merck & Co., Inc. including, among others, the extent to which
Rosetta Inpharmatics' technology platform can be used in drug
discovery programs, uncertainty of market acceptance of Rosetta
Inpharmatics' technologies, ability to compete against existing
technologies, and those mentioned in the cautionary statements in
Item 1 of Merck's Form 10-K for the year ended Dec. 31, 2005, and in
its periodic reports on Form 10-Q and Form 8-K (if any) which are
incorporated by reference.

Rosetta Resolver and Rosetta Elucidator are U.S. registered
trademarks of Rosetta Inpharmatics LLC. Rosetta Syllego is a
trademark of Rosetta Inpharmatics LLC.

Yahoo! Groups Links

<*> To visit your group on the web, go to:

<*> To unsubscribe from this group, send an email to:

<*> Your use of Yahoo! Groups is subject to:

Biotech News - Kane Biotech Announces Increase to Private Placement Offering

------------------------ Yahoo! Groups Sponsor --------------------~-->
Protect your PC from spy ware with award winning anti spy technology. It's free.

Kane Biotech Announces Increase to Private Placement Offering
WINNIPEG, MANITOBA -- (MARKET WIRE) -- 05/26/2006 -- Kane Biotech
Inc. (TSX VENTURE: KNE) (the "Company"), a leading biofilm company,
today announces an increase in the size of its previously announced
private placement offering (the "Offering") of up to 2,181,818 units
("Units") at a price of $0.55 per Unit for gross proceeds of up to
$1,200,000. Due to strong demand for the Offering, the Company has
determined to increase the size of the Offering to 2,727,273 Units
at a price of $0.55 per Unit for gross proceeds of up to $1,500,000.
Each Unit will still be comprised of one common share of the Company
(a "Share") and one half of one Share purchase warrant
(a "Warrant"). Each whole Warrant will entitle the holder thereof to
purchase one Share at a price of $0.70 per Share for a period of 18
months from the date of issuance of the Warrant. All other terms of
the Offering remain the same.

The Offering is subject to receipt of all necessary approvals,
including the approval of the TSX Venture Exchange.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development
of products to prevent and disperse bacterial biofilms. Biofilms
develop when bacteria, and other microorganisms, form a protective
matrix that acts as a shield against attack. When in a biofilm,
bacteria become highly resistant to antibiotics, high temperatures
and host immune responses. This resiliency contributes to human
health problems such as recurrent urinary tract infections, medical
device associated infections and tooth decay.

Certain information contained in this press release may be forward-
looking and is subject to risks and uncertainties. Although the
Company believes that the expectations contained herein are
reasonable, it can give no assurances such forward-looking
statements will prove correct. Information is provided from sources
deemed to be reliable.

Yahoo! Groups Links

<*> To visit your group on the web, go to:

<*> To unsubscribe from this group, send an email to:

<*> Your use of Yahoo! Groups is subject to:

Saturday, May 27, 2006

Biotech News - Governor signs biotech jobs act

------------------------ Yahoo! Groups Sponsor --------------------~-->
You can search right from your browser? It's easy and it's free. See how.

Governor signs biotech jobs act

The Biotechnology Jobs Growth Act of 2006, a bill sponsored by
legislative leaders to attract and keep biotechnology and
biomanfacturing firms in Rhode Island, is headed to the governor's

The legislation was transmitted to the governor Tuesday by both the
House and the Senate, after it passed in concurrence in the House
Tuesday and in the Senate May 16.

The governor scheduled a signing ceremony for the bill Wednesday in
the State Room on the second floor of the State House.

The legislation focuses on the economic incentives that – coupled
with physical infrastructure investments and the availability of
skilled labor – are viewed as critical to attracting biotech and
biomanufacturing investment. The bill extends the biotechnology tax
credits period from seven to 15 years, making Rhode Island tax
policy competitive with that of Connecticut, Massachusetts, New
Jersey, New York and Pennsylvania.

Yahoo! Groups Links

<*> To visit your group on the web, go to:

<*> To unsubscribe from this group, send an email to:

<*> Your use of Yahoo! Groups is subject to:

Biotech News - BASF expands crop biotech capabilities

------------------------ Yahoo! Groups Sponsor --------------------~-->
Home is just a click away.  Make Yahoo! your home page now.

BASF expands crop biotech capabilities

BASF's acquisition of CropDesign, a Belgian biotech company, will help
establish the German chemical giant as a leader in the development of
important crop traits in corn, soy bean and rape seed.

The acquisition complements BASF Plant Sciences existing gene
discovery activities and extends its position in access to
agronomically important genetic traits. CropDesign specialises on
traits for yield-enhancement, drought tolerance and improved nutrient
use efficiency of crops such as corn and rice.

Yahoo! Groups Links

<*> To visit your group on the web, go to:

<*> To unsubscribe from this group, send an email to:

<*> Your use of Yahoo! Groups is subject to:

bioMerieux Sells Durham Operation to Irish Biotech Firm

bioMerieux Sells Durham Operation to Irish Biotech Firm
Special To LTW
DURHAM, N.C. – French life sciences firm bioMerieux is selling its operation in Durham as part of a larger transaction with Ireland-based Trinity Biotech.Trinity said operations in Durham would be transferred to Ireland. Biomerieux operations in St. Louis that are also part of the deal will be transferred to a site in New York.

Biotech News

Biotech News - Oncolytics Biotech gets US patent for Reovirus tech

Biotech News - Oncolytics Biotech gets US patent for Reovirus tech
Saturday, May 27, 2006 10:00 IST
Calgary, Canada

Oncolytics Biotech Inc. has been granted US Patent 7,049,127 entitled "Method of Producing Infectious Reovirus." The claims describe a method for producing and purifying mammalian Reovirus.

"Effective production methodologies are essential for the development of Reolysin," said Dr. Matt Coffey, chief scientific officer of Oncolytics. "This patent adds continued protection for key pieces of our growing intellectual property estate."

Oncolytics is a Calgary-based biotechnology company
Biotech News

Tuesday, May 23, 2006

Biotech News - CED Biotech 2006 Exhibitor and Sponsor Profiles

Yahoo! Groups My Groups | biotech-news Main Page

CED Biotech 2006 Exhibitor and Sponsor Profiles

5/22/2006 1:00:00 PM EST


CED Biotech 2006 takes place May 22-23, 2006, in Winston-Salem, NC, at the Benton Convention Center.

For in-depth information about the event, visit

Below are profiles from CED Biotech 2006 exhibitors and sponsors; breaking news releases are available at, Business Wire's trade show, conference and event news resource.

Business Wire is the official news wire service for CED Biotech 2006.

Company: Charter Medical, Ltd Ticker Symbol & Exchange: LDL: NYSE Media Contact: Jennifer Reddick Phone: 336-714-4215 E-mail: 336-714-4241 Web:  Experts in vital fluids management, Charter Medical Ltd. manufactures and markets innovative products for separating, containing and transporting vital fluids in the Biotech and Pharmaceutical Industries. The Charter Bio-PakT line of flexible processing containers is designed for the sterile containment of high-value fluids in biopharmaceutical processes. Containers are 100% integrity tested and range from 30ml to 2000+ liters in a variety of shapes. Charter also offers fluid sampling and container handling accessories, including stainless-steel containers, and collapsible totes. Charter can also design to customer specifications, with fast turnaround and a high level of customer service.  Company: Cherry, Bekaert & Holland, L.L.P. Media Contact: Sheila Ogletree, Partner Phone: 919-782-1040 Email: Web:  Cherry, Bekaert & Holland, L.L.P. (CB&H) is excited to be a Sponsor of CED's Biotech 2006 Conference. CB&H is the 25th largest Certified Public Accounting firm in the nation with offices located throughout the Southeast. CB&H is the Firm of Choice for many growing businesses who appreciate personalized service with the resources of a larger firm. CB&H's Raleigh, North Carolina office specializes in providing professional audit, accounting, tax and business consulting services to growing and mid-sized companies in the risk management, information technology and government contracting arenas.  Company: FreeMind Consultants Media Contact: Jason Kanar, Marketing Director Phone: 617-395-0248 E-mail: Web:  FreeMind is an international consultancy firm that specializes in raising funds from government sources, mainly the NIH in support of its client's research activities. FreeMind's clientele includes universities, research institutions and companies. Through a systematic process, due to our vast experience and knowledge, FreeMind maximizes our client's dollar potential. FreeMind employs top grant writing and life science experts, all focused on turning great science into multi-million dollar winning applications. The US Funds Division, with its combined years of experience working with NIH and other funds, has designed a structured grant writing process aimed at perfecting our clients' grantsmanship.  Company: Hutchison Law Group PLLC Media Contact: Andrea Cook Investor Relations Contact: Andrea Cook Phone: 919-829-4285 E-mail: Web:  Hutchison Law Group is the leading provider of strategic business and intellectual property counsel to the Southeast's technology community. Hutchison Law Group partners with its clients to provide responsive quality service, strategic advice, creative problem-solving and connections to investors. Hutchison Law Group understands its clients' technologies and the unique opportunities and challenges they face. Hutchison Law Group's attorneys play a key role creating an environment and infrastructure that breed success.  Company: NC SBTDC Media Contact: John Ujvari, MBA Phone: 919-962-0389 E-mail: Web:  The North Carolina Small Business and Technology Development Center (SBTDC) is the primary provider of assistance to North Carolina firms interested in pursuing SBIR and STTR funding. Noted below are specific tools provided via the NC SBTDC: Source of Program Information, Counseling, Proposal Reviews, Workshops & Conferences, Follow-on Services. A SBIR/STTR Phase 1 and 2 proposal training session will be held on June 7th (afternoon) and June 8th (morning) in RTP at the NC Biotech Center. Registration Only $69 For Both Days! More info at  Company: PricewaterhouseCoopers LLP Media Contact: Jeff Barber, Managing Partner, Raleigh, NC /                Laura Troy, Marketing, Raleigh, NC Phone: 919-755-3000 E-mail: / Company URL:  PricewaterhouseCoopers LLP is the world's largest professional services organization, drawing on the knowledge and skills of more than 130,000 people in 148 countries. We provide industry-focussed assurance, tax and advisory services for public and private clients primarily in four areas: corporate accountability, risk management, structuring mergers and acquisitions and performance and process improvement. Our use of our networks, experience, industry knowledge and business understanding in each of these areas distinguishes the way we work. We support growth and business goals by structuring creative financing methods to meet growth models, assist in formulating business strategies and plans, advise in mergers and acquisitions and partnership arrangements, help build management teams, provide answers to questions regarding expansion, assist with the planning of an initial public offering and subsequent SEC activities, and advise on other business requirements as needed.  Company: Shelco Media Contact: Bud Palmer Phone: 336-760-5009 E-mail: Web:  Shelco is a full service General Contractor with 5 offices covering the Carolinas. Even with being a regional firm, our $300,000,000 in volume puts us in the top 150 construction companies in America. We are a relationship oriented company and 75 percent of our work is with repeat customers. Our work covers a diverse spectrum which includes class "A" offices, medical, biotech/pharma, R&D, retail, industrial, institutional and upfit/renovation. We invite you to inspect our latest work in the new world class Wake Forest University Health Sciences Biotech Research Facility in the Piedmont Triad Research Park here in Winston Salem.  Company: UBS Financial Services, Inc. Ticker Symbol & Exchange: UBS Media Contact: James F. Seramba Investor Relations Contact: James F. Seramba Phone: 336-834-6900 E-mail: Web:  UBS is one of the world's largest wealth managers and a leading global investment banking and securities business. In working with its clients, UBS can provide access to the extensive global resources of one of the world's largest wealth management firms thus giving them the benefit of a wide variety of products and services targeted specifically to their unique needs and goals.  Company: Wyrick Robbins Yates & Ponton LLP Public Relations Contact: MaryLou Rothfuss, Marketing Coordinator Investor Relations Contact: Kenneth E. Eheman, Jr., Esq. Phone: 919-781-4000 E-mail: / Company URL:  Wyrick Robbins Yates & Ponton LLP is proud to sponsor BIOTECH 2006. Founded over 25 years ago, Wyrick Robbins is the region's leading law firm representing high-impact technology and life sciences companies, with focused practice groups that maximize the growth opportunities for all levels of business -- from start-up to publicly held companies. Business North Carolina recently recognized 7 of our attorneys in its "Legal Elite" for 2006. Our focus on technology and life sciences companies, and the depth of experience we have collected, enables us to contribute not just legal advice, but structural and bottom-line business advice that is critical to the growth of these businesses. Wyrick Robbins Yates & Ponton LLP - Our Business is Law.


Biotech News - Biotech Conference draws strong crowd

------------------------ Yahoo! Groups Sponsor --------------------~-->
Everything you need is one click away.  Make Yahoo! your home page now.

Biotech Conference draws strong crowd
The Business Journal of the Greater Triad Area
by Matt EvansThe Business Journal

The move of North Carolina's biggest biotechnology event from
Research Triangle Park to Winston-Salem this year apparently hasn't
deterred the industry's heavy hitters from attending.

Officials with the Council for Entrepreneurial Development, which
organized the two-day Biotech 2006 event that wraps up Tuesday at
the Benton Convention Center, said 830 people had registered by the
end of the day Monday. Registration was to remain open through
lunchtime Tuesday, when National Public Radio science journalist Ira
Flatow is scheduled to deliver a featured address.

This is the first time the CED event has been held outside of
Research Triangle Park, the state's main biotech hotbed. At last
year's meeting, CED counted just over 800 attendees.

Yahoo! Groups Links

<*> To visit your group on the web, go to:

<*> To unsubscribe from this group, send an email to:

<*> Your use of Yahoo! Groups is subject to:

Sunday, May 21, 2006

Biotech News - The Reporter - State still a breeder for biotech

Yahoo! Groups My Groups | biotech-news Main Page


State still a breeder for biotech

By Amanda Janis/Business Writer

Investors' disinterest in California's established biotechnology clusters has played prominently in recent local headlines.

Industry leader Genentech chose to build its new $250 million facility in Oregon, where corporate income tax structures are more favorable. Then there was the start-up firm that passed on Vacaville in order to capitalize on biotech tax breaks offered in Washington. And most recently Chiron parent Novartis announced it would build a $400 million vaccine plant in the United States, but not in California.

"There were requests for proposals from Roche for a similar kind of vaccine plant about six months ago," recalled Mike Ammann, president of the Solano Economic Development Corp. An economic analysis performed at the time found that if the proposed Roche plant were to locate in Solano County - which it will not - the $262.5 million facility would generate more than 10,000 full- and part-time jobs and have a total local economic impact of $1.2 billion in its first year of operation.




Biotech News - Researchers Link Two More Genes To Sudden Infant Death Syndrome

Yahoo! Groups My Groups | biotech-news Main Page

Researchers Link Two More Genes To Sudden Infant Death Syndrome

Recent discoveries at Mayo Clinic added two more cardiac genes to the list of potential links to sudden infant death syndrome (SIDS), increasing the possibility that genetic defects of the heart may cause up to 15 percent of SIDS cases. This research will be presented Friday at Heart Rhythm 2006, the 27th Annual Scientific Sessions of the Heart Rhythm Society in Boston.

In the two recent separate studies, researchers examined caveolin-3 (CAV3) and the cardiac ryanodine receptor (RyR2) and found molecular and functional evidence in both to implicate them as SIDS-susceptibility genes. Researchers examined the tissue of 135 unrelated cases of SIDS -- in infants with an average age of 3 months old -- that had been referred to Mayo Clinic's Sudden Death Genomics Laboratory for molecular autopsy. In each study, two of the 135 cases possessed mutations in either CAV3 or RyR2.

SIDS -- the sudden, unexplained death of an infant under 1 year old -- is estimated to cause 2,500 infant deaths each year. "Combined with our previous discoveries, we now estimate that defects in genes that provide the blueprints for the critical controllers of the heart's electrical system might have played a key role in more than 300 of those tragedies," says Michael J. Ackerman, M.D., Ph.D., principal investigator of both studies and director of Mayo Clinic's Long QT Syndrome Clinic and Sudden Death Genomics Laboratory. "We are continuing to expose the causes of SIDS. So far, we have now added six genes to the SIDS most-wanted list."



Biotech News - Unique Life Science Center Rises from the Desert

Unique Life Science Center Rises from the Desert

Biotech News

Unique Life Science Center Rises from the Desert

Arizona State University has created a multidisciplinary lab that it plans to use to build a world-class biotechnology infrastructure for the area.

Like the mythical bird noted above, the Biodesign Institute at Arizona State University (ASU) located in Tempe, just southeast of Phoenix, very quickly has established an “intense excitement” within the life science research community. The Institute was founded in 2002 and housed initially in temporary quarters, so long before its current facility was completed, its administrators were able to scan the research community and collect a core group of world-class intellectual re-searchers. They’re now building upon that R&D infrastructure within their newly occupied research facility.

The structure that is the Biodesign Institute boasts a design that promotes interdisciplinary research, laboratory flexibility, operational sustainability, support for advanced science and technology development, researcher recruitment, and aesthetic design. The Biodesign Institute is clearly a unique facility and the recipient of this year’s R&D Magazine Laboratory of the Year award. The 2006 Lab of the Year awards are particularly notable in that this is the 40th annual awards presentation, which were presented to the lab designers and owners in an awards ceremony and reception at R&D’s Laboratory Design Conference in Atlanta on April 4, 2006.

A vision and a plan
It’s particularly fitting that the Biodesign Institute is the 40th Lab of the Year, because the Institute represents more than just a well-designed and planned facility. Like the phoenix, the Biodesign Institute is the embodiment of Arizona’s vision for what the state wants to become in the future—a global center for life science research and commerce. Bud Guest, SVP at McCarthy Building Companies, St. Louis, Mo., and a judge in this year’s competition recognized this value. “With its excellent functionality and truly multidisciplinary design, the Biodesign Institute is destined to make a positive contribution to development of the biotech industry in Arizona,” he says.
Biodesign Institute uses glass to bring natural light inside the building and “connect itself” to its community.

Thursday, May 11, 2006

Biotech News - Government requires biotech company to do more studies on anthrax vaccine

Yahoo! Groups My Groups | biotech-news Main Page

Government requires biotech company to do more studies on anthrax vaccine



By Steve Johnson

Mercury News

The federal government's two-year-old effort to protect the nation against bioterrorism hit a speed bump Wednesday after officials asked for more studies from VaxGen, a Bay Area biotech company funded to develop a new anthrax vaccine.

Under the first and biggest contract awarded under President Bush's highly publicized Project Bioshield, VaxGen was awarded $877.5 million in 2004 to make 75 million doses of a new type of anthrax vaccine.

But on Wednesday, VaxGen executives said the government is now demanding the company pay for additional costly studies which could threaten VaxGen's financial health and deter other biotech firms from participating in the bioshield effort.

Noting that VaxGen won't be paid under the contract until it delivers the vaccine, company executives said the demand for additional studies could delay the drug's production at least a year. They said the contract changes are particularly troubling because federal authorities have not cited any problems with VaxGen or its vaccine in demanding the additional studies.

Biotech News


 Arizona Biotech





Biotech News - Biotech progress overlooked - Rosy report on industry ignores Arizona

------------------------ Yahoo! Groups Sponsor --------------------~-->
Home is just a click away.  Make Yahoo! your home page now.

Biotech progress overlooked
Rosy report on industry ignores Arizona

Biotech progress overlooked
Rosy report on industry ignores Arizona

Max Jarman
The Arizona Republic
Apr. 9, 2006 12:00 AM

At 30, America's biotech industry is growing, becoming more stable
and nearing the elusive break-even point.

Since America's first biotech company, Genentech Inc., was formed
April 7, 1976, it has developed into a $50 billion-a-year industry,
with annual revenue growth that has ranged in the past three years
from 16 to 19 percent.

At roughly 5 years old, Arizona's emerging biotech and bioscience
industries show surprising signs of vitality and growth. The number
of Arizona bioscience companies is growing, grant funding is sharply
up and related employment grew 12 percent from 2000 to 2004 to about
72,000 total jobs. advertisement

Work on new drugs drew a record level of grants from the National
Institutes of Health. Grants to researchers in the state rose 30
percent from 2001 to 2004 and now total more than $160 million.

Yet despite the strides Arizona has made toward becoming a major
biotech hub, it remains unmentioned in national reports on biotech.

Accountant Ernst & Young's annual Global Biotechnology Report 2006
makes no mention of the state in its assessment of the country's top
15 biotech areas, which include neighboring states of Colorado and
Utah. The San Francisco Bay area heads the list of locations ranked
by the number of public biotech companies located in the area. New
England and San Diego rounded out the top three with Texas, Colorado
and Utah at the bottom at 13th, 14th and 15th.

Arizona wasn't even mentioned in the "other" category, which
included the states of Hawaii, Minnesota, Missouri, Montana,
Nebraska, Nevada, Oklahoma and South Dakota.

Walter H. Plosila, vice president of the technology partnership
practice for the bioscience and technology consulting firm Battelle,
noted that the Ernst & Young study looks at biotechnology, which is
largely research and testing.

"This is only a narrow slice of the pie that Arizona is pursuing,"
Plosila said. "Arizona is developing its broader bioscience sector,
which also includes drugs and pharmaceuticals, medical devices,
hospitals and labs, and agricultural biotech."

Batelle is the author of the Arizona Bioscience Roadmap, which is
guiding the state's efforts to become a bioscience industry center.

Martin Shultz, chairman of the Arizona Bioscience Roadmap Steering
Committee, noted that Arizona is a relative latecomer to the
bioscience arena and it's not surprising that it has not been
recognized in the Ernst & Young report. The report ranks areas
according to the number of public biotech companies they support,
and so far Arizona doesn't have a critical mass of those types of

Yahoo! Groups Links

<*> To visit your group on the web, go to:

<*> To unsubscribe from this group, send an email to:

<*> Your use of Yahoo! Groups is subject to:

Biotech News - ASU, GateWay work to speed up biotech training

------------------------ Yahoo! Groups Sponsor --------------------~-->
Everything you need is one click away.  Make Yahoo! your home page now.

ASU, GateWay work to speed up biotech training

By Angela Gonzales
The Business Journal of Phoenix

An agreement between Arizona State University and GateWay Community
College will allow biotech students to enter the work force more
quickly, without hassling with credits as they transfer from the
community college to the university.

Easing the transition for students comes at a time when biotech
leaders say Arizona's current work force is not properly prepared to
compete in a bioscience and biotechnology economy.

Yahoo! Groups Links

<*> To visit your group on the web, go to:

<*> To unsubscribe from this group, send an email to:

<*> Your use of Yahoo! Groups is subject to:

Biotech News - Avantogen and Hawaii Biotech Combine Vaccine Businesses

------------------------ Yahoo! Groups Sponsor --------------------~-->
Everything you need is one click away.  Make Yahoo! your home page now.

Avantogen and Hawaii Biotech Combine Vaccine Businesses; World-Class
Vaccine Developer is Created to Accelerate Pandemic Influenza, West
Nile and Dengue Fever Vaccine Programs

Avantogen Limited (Avantogen)(ASX:ACU), and Hawaii Biotech, Inc.
(Hawaii Biotech), a privately held company, closed today on the
Definitive Agreement executed and announced on March 14, 2006,
combining their respective vaccine businesses. The Company will
continue to be known as Hawaii Biotech, Inc., and is 50% owned each
by Hawaii Biotech's current shareholders and Avantogen Limited. Both
Avantogen and Hawaii Biotech's shareholders gave approval for the

The combined business will incorporate both Avantogen's and Hawaii
Biotech's complementary technologies, and will maintain the existing
corporate headquarters and vaccine development laboratories in Oahu,
Hawaii, as well as an office in California.

Under terms of the agreement, Avantogen contributed US $3.5 million
in cash, its vaccine adjuvant program (currently in Phase I human
trials) and Pentrys vaccine program (currently in Phase II human
trials), and its senior management team, while Hawaii Biotech
contributed its vaccine research and development team, its pre-
clinical vaccine programs and facilities, its vaccine grant funding,
and US $1 million in cash. Under certain circumstances applicable to
both Avantogen and Hawaii Biotech, equity ownership of the newly
combined company can be adjusted to 60%-40% in either direction.

Following a meeting of the new Hawaii Biotech, Inc. Board of
Directors, Leonard Firestone, M.D., an experienced biotech
executive, was named CEO of Hawaii Biotech, Inc., while Carolyn
Weeks-Levy, current VP of Research, Development, and Regulatory
Affairs and leader of Hawaii Biotech's vaccine programs, was named
its Chief Scientific Officer. David G. Watumull, Hawaii Biotech's
former CEO, has become CEO of Cardax Pharmaceuticals, Inc., an anti-
inflammatory small molecule development business in Honolulu, which
was spun out of Hawaii Biotech and is wholly owned by the pre-
combination Hawaii Biotech shareholders.

Hawaii Biotech's Board members are: Avantogen Chairman Richard Opara
(Chairman), Nicholas Mitsakos, Hawaii Biotech's former Chairman;
Leonard Firestone, M.D., CEO; Joseph Boystak, former Managing
Director with Jefferies & Co and now with Chopin Capital Partners;
and Richard Foster, who will continue to serve as Director.

The CEO, Dr. Firestone, commented: "This business combination was
driven by scientific, fiscal, and corporate synergies, and has
created a truly world-class vaccine development company. Hawaii
Biotech's scientific team has capabilities with recombinant
technology that can uniquely and genuinely address the spectre of
pandemic viral disease. The Company's exceptional manufacturing
platform will allow us to lead the marketplace, by rapidly
delivering the quality and quantity of vaccine product needed for
viral pandemics such as Influenza. These same manufacturing methods
will also support the development of our valuable West Nile and
Dengue Fever vaccine products, both of which we expect to enter the
clinic in 2007."

About Hawaii Biotech's Vaccine Business

Hawaii Biotech's vaccine development platform is based on production
of proprietary antigens (proteins) that, when appropriately
adjuvanted, provoke immune responses equivalent to, or better than,
traditional live or inactivated viral vaccines -- with a
significantly improved safety profile. During the past 3 years,
Hawaii Biotech received funding commitments of over US $30 million
from the U.S. National Institutes of Health and other governmental
agencies, to develop vaccines to prevent human infection by the West
Nile virus, Dengue Fever virus, pandemic and annual Influenza
viruses, and other serious incurable diseases including hepatitis C,
malaria, Tick-borne and Japanese encephalitis, Ebola, and Eastern
equine encephalitis.

About Avantogen's GPI Adjuvant

Avantogen's GPI-0100 product, a triterpene saponin, is currently
under license to Pfizer Animal Health, Inc., Endocyte, Inc.,
University of Alabama, and Memorial-Sloan Kettering Cancer Center,
to boost immune responses to their respective vaccine-based products
under development.

About Avantogen, Ltd.

Avantogen (formerly Australian Cancer Technology) is an
international biotechnology company developing a broad oncology-
related product portfolio. Avantogen has acquired the North American
marketing rights for RP101, a promising pancreatic cancer drug
currently in Phase II clinical studies through a subsidiary company,
Resistys Inc, a joint venture with Bioaccelerate of New York.
Avantogen's Pentrys(R) anti-cancer vaccine is being evaluated in
prostate cancer patients in Phase IIb clinical studies and the
company is advancing several immune enhancing adjuvants in three
Phase I cancer trials. The immune enhancing adjuvants were developed
by Galenica, a privately held U.S. vaccine developer. Avantogen
acquired Galenica in July 2004. The company also markets Revisys(R),
a branded line of medical nutritionals designed for people with
special needs, including those undergoing cancer treatments.
Avantogen is traded on the Australian Stock Exchange (ASX) under the
symbol ACU. The company has established a Level 1 ADR stock program
in the U.S. trading under the symbol AUCJY and is listed on the
Xetra exchange, the electronic trading system of the Frankfurt Stock
Exchange, trading under the symbol CBS. For further information,

About Pandemic Influenza and "Bird Flu"

The Centers of Disease Control (CDC) defines an influenza pandemic
as a global outbreak that occurs when a new, virulent influenza A
virus "emerges" in the human population, and spreads easily from
person to person worldwide. Local outbreaks of "bird flu" may be a
source of a new flu virus. Pandemics are different from seasonal
outbreaks or "epidemics" of influenza. Seasonal outbreaks are caused
by subtypes of influenza viruses that already circulate among
people, whereas pandemic outbreaks are caused by new subtypes
that "emerge," or by subtypes that haven't circulated among people
for a long time, or ever. Past influenza pandemics have led to high
levels of illness, death, social disruption, and economic loss. The
severity of the next pandemic cannot be predicted, but models
suggest that in the absence of any control measures (e.g.,
vaccination), a "medium-level" pandemic in the U.S. could cause 89 -
207,000 deaths, 314 - 734,000 hospitalizations, 18 - 42 million
outpatient visits, and another 20 - 47 million people being sick.
Between 15% and 35% of the U.S. population could be affected by an
influenza pandemic, and the economic impact could range between
$71.3 and $166.5 billion.

Forward-Looking Statements

Statements contained in this press release that are not historical
information are forward-looking statements as contemplated by the
Private Securities Litigation Reform Act of 1995. Such forward-
looking statements are subject to risks and uncertainties that could
cause actual results to differ materially from those projected or
implied. Such potential risks and uncertainties relate, but are not
limited to, the results of clinical trials, product demand and
market acceptance, the impact of competitive products and pricing,
effectiveness and pace of current and future product development,
and regulatory approval. More detailed information on these and
additional factors that could affect Avantogen's business, prospects
and operating and financial results are described in Avantogen's
annual reports filed or to be filed with the Australian Stock
Exchange. Avantogen urges all interested parties to read these
reports to gain a better understanding of the many business and
other risks that the company faces. For further information visit The historical results achieved by the company
are not necessarily indicative of its future prospects. The company
undertakes no obligation to publicly update or revise any forward-
looking statements, whether as a result of new information, future
events or otherwise.

Hawaii Biotech, Inc. Leonard Firestone, M.D., 808-486-5333

Yahoo! Groups Links

<*> To visit your group on the web, go to:

<*> To unsubscribe from this group, send an email to:

<*> Your use of Yahoo! Groups is subject to:

Saturday, May 06, 2006

Biotech News - Breakthrough innovations honoured: The European Inventor of the Year 2006

------------------------ Yahoo! Groups Sponsor --------------------~-->
Home is just a click away.  Make Yahoo! your home page now.

Breakthrough innovations honoured: The European Inventor of the Year

Almost 400 visitors gathered at the spectacular Autoworld Museum in
Bussels on 3 May to see EPO President Alain Pompidou and European
Commission Vice President Günter Verheugen honour the European
Inventors of the Year 2006 at the first-ever awards ceremony
organised jointly by the two institutions.

Speaking at the award ceremony, EPO President Alain Pompidou said
that inventors "should be treated like pop stars". He described the
event as "historic". Commission Vice President Günter Verheugen said
he hoped that the awards would establish themselves as a "tradition"
in the Belgian capital and would one day be "as prestigious as the
Nobel Prize".

Among the guests were representatives from the European Commission,
the European Parliament, SIPO, OAPI, ARIPO and European industries
as well as Nicole Fontaine, the former president of the European
Parliament. The European media was also well represented with 30
print journalists and camera crews in attendance at the gala
following an announcement of the event at a joint press conference
in the Commission press room earlier in the day.

Awards were presented in six categories and the European Inventors
of the Year 2006 are:

Zbigniew Janowicz and Cornelis Hollenberg (Rhein Biotech,
Düsseldorf, Germany), who developed a process for producing foreign
proteins in Hansenula yeasts, a key component in the production of
hepatitis B vaccines. The new technology is now an acknowledged
standard, helping to combat the worldwide spread of hepatitis B,
which according to WHO estimates affects around a third of the
world's population. Over 450 million doses of the vaccine have now
been sold in 90 countries. They were honoured in the
category "Industry".

Stephen P.A. Fodor, Michael C. Pirrung, J. Leighton Read and Lubert
Stryer (Affymax, Netherlands), who revolutionised biotechnology with
their invention of the DNA chip while working for the Dutch company
Affymax's US research institute. They succeeded in storing vast
amounts of biological data on a small glass chip (polymer
synthesis). Today, as a result, a great many experiments can be
conducted at the same time on a single DNA chip. The invention is
primarily used to detect genetically determined disease. The jury
selected this team for the category "Small and Medium-sized

Peter Grünberg (Jülich Research Centre, Germany), who identified the
giant magnetoresistance effect (GMR), which allowed a fifty-fold
increase in the usable storage density of hard disks. The fruits of
his research in information technology are now to be found in nearly
all commercially available PCs, digital cameras and MP3 players. He
was declared the winner in the category "Universities and research

John Edward Starrett, John Martin, David Tortulari, Joanne Bronson
and Mutzamil Mansurin (Academy of Sciences of the Czech Republic,
Prague) at the Institute of Organic Chemistry and Biochemistry, who
succeeded in producing innovative prodrugs of phosphonates, which do
not unleash their full effect until transformed in the human body.
They are due to be deployed against viral infections and in tumour
therapy. The team took home the award for "New EU member states".

Larry Gold and Craig Tuerk (NeXstar Pharmaceuticals, Boulder, USA)
who, with their SELEX technology, invented an important screening
process used in biochemistry to find unique oligonucleotides capable
of binding to specific proteins that cause disease. This pioneering
invention led to an aptamer or drug called Macugen which has eye
treatment applications and is due to be approved in Europe soon. It
is hoped that SELEX technology will also result in drugs for cancer
therapy and prove useful in the fight against AIDS. The American
inventors were awarded the trophy in the category "Non-European

Federico Faggin (Italy; Santa Clara, USA) developed the first
microprocessor chip, allowing huge volumes of data to be processed
and unleashing a revolution in computer technology. He has filed 27
patent applications over the course of his distinguished career.
Federico Faggin was presented with the European Inventor of the Year
award for "Lifetime achievement".
The awards gala was held as part of a two-day conference, which
provided a unique forum for exploring the role of patents in
promoting innovation in Europe. Around 140 high-level experts from
Europe, the United States and Asia attended the conference to
discuss the future of the European patent system and the challenges
that China's emergence presents.

For more information, please visit:

Yahoo! Groups Links

<*> To visit your group on the web, go to:

<*> To unsubscribe from this group, send an email to:

<*> Your use of Yahoo! Groups is subject to:

Biotech News - RNCOS Research: The budding India's biotech hub Hyderabad

Yahoo! Groups My Groups | biotech-news Main Page

The budding India's biotech hub Hyderabad


RNCOS Research Opening up of the Genome valley in Hyderabad is a clear indication that Indian biotechnology market is going to boom in the near future...

NEW DELHI, INDIA, May 06, 2006 - RNCOS Research Spreading over 600sq km, the genome valley in Hyderabad is developing into the first technologically advanced biotech huddle for life science activities such as research, training and manufacturing in India. The valley will accommodate international life science institute, a biotech incubation center for start-ups and a top-notch animal resource facility and several among other amenities. Almost 50 biotech companies, which include several MNCs, have already established their units in this huddle.

A syndicate of companies is providing financial support to this endeavor. Initially, the government had allotted 100 acres land for the life science research facility. However, the government has also allotted 300 acres of land for the third phase of the biotech park, as two phases have already been occupied.

As per a recent market research report named "Indian Biotechnology Market Outlook (2006)" published by RNCOS, "With an amount of $30 million, the state has also launched India's first biotech business enterprise fund. It has been introduced as a joint venture between Dynam Venture East, USA and Andhra Pradesh Industrial Development Corporation (APIDC) Venture Capital Ltd to subsidize start-up biotech firms".

As per experts, "The consumption of biotechnology products in India will reach $1.52bn and $4.53bn by the years 2007 and 2010".

The report is useful for both the investors as well as the entrepreneurs, as it includes:

· The company profiles of 20 leading firms including Biocon, Wockhardt, Bharat Biotech, Zydus Cadila, and Aventis Pharma etc in the biotech sector.
· Thorough analysis of the biotech market, in terms of demand, exports, size and domestic market, in India for the year 2005.
· Region wise analysis of biotech market in India is also covered.
· A comprehensive discussion of the initiatives and policies taken up by the state and central governments to support this industry is also included in this report.
· The future prospects and set of opportunities for the growth of the biotech industry in India plus various challenges the industry is facing at present are covered in this report.
· Forecast till the year 2010.

For more information about the report please visit

RNCOS, formed in 2002, offers Market Research Reports for your business needs and aims to put an end to your information pursuit. Our expertise in gathering global business information for industry research, corporate training, growth consulting, and business consulting, brings reputed companies and firms to us for business enhancement solutions. We can be your one-stop-shop for Industry research information and niche market analysis.


Biological research prevalent in Scottsdale

Biological research prevalent in Scottsdale
By Lindsay Butler, Tribune
April 30, 2006
The cure for cancer could be discovered on Shea Boulevard. The central Scottsdale corridor is home to some of the most cutting-edge biological research focused on improving medical treatment.

Biotech’s growth in Scottsdale is no coincidence, say city leaders who have been working for years to transform the city’s reputation to include more than the perfect tan or Coach store.

“That tourism base remains an incredibly strong and large component with the profile of businesses in Scottsdale. But it’s no longer the tail wagging the dog,” said Rick Kidder, president of the Scottsdale Area Chamber of Commerce. Two of the Valley’s three main players in the biotech field are in Scottsdale: The Mayo Clinic Scottsdale is providing an area for top scientists to work under the same roof, while Scottsdale Healthcare is pioneering an effort to develop new cancer treatments.

It won’t just be corporations or cities that benefit. For example, local medical patients will be among the first to try out new cancer drugs, industry leaders said.

Although the Valley is emerging in the biotech industry, Scottsdale is moving the fastest.

Mayo Clinic set stage for booming biotech

Mayo Clinic set stage for booming biotech
By Mark Scarp, Tribune Columnist
May 3, 2006

Today Scottsdale is making a national name for itself in biotech research. The roots of that reputation are squarely planted in 1985, when officials of the legendary Mayo Clinic announced they would open one of its first branches here.

Scottsdale’s first big step beyond a sunny Old West themed resort town toward being a city with a global reputation can be traced to this event. Mayo’s opening in 1987 was the foundation of Scottsdale’s becoming a major medical research hub — and, arguably, it was the vanguard of the recreational, residential and commercial growth of north Scottsdale.

Biotech News - Biotech Cotton Provides Same Yield with Fewer Pesticides

Yahoo! Groups My Groups | biotech-news Main Page

Biotech Cotton Provides Same Yield with Fewer Pesticides



Arizona farmers receive the same yield/acre, use fewer chemical insecticides and maintain insect biodiversity when they plant the biotech cotton known as Bt cotton, according to new research. The finding comes from the first large-scale study that simultaneously examined how growing Bt cotton affects yield, pesticide use and biodiversity. 

Arizona farmers receive the same yield/acre, use fewer chemical insecticides and maintain insect biodiversity when they plant the biotech cotton known as Bt cotton, according to new research.

The finding comes from the first large-scale study that simultaneously examined how growing Bt cotton affects yield, pesticide use and biodiversity.

It's good news for the environment.

"What we see is that it's positive here in Arizona -- no doubt about it," said Yves Carrière, an associate professor of entomology at The University of Arizona in Tucson. "We've reduced pesticide use in Arizona. We've wanted to do that for 25 years."

Bt cotton has been genetically altered to produce Bt toxin, a naturally occurring insecticide that kills pink bollworm, a major pest of cotton. Bt cotton has been planted in Arizona since 1996. Now more than half of the state's 256,000 acres of cotton fields are planted with the biotech plants.

Some have suggested that, in addition to killing the target pests, insecticide-containing crops like Bt cotton would also kill beneficial and non-target arthropods.

The new study found that Bt cotton, also known as transgenic cotton, does not affect the biodiversity of insects in cotton fields.

Carrière said, "There were lots of factors that affected biodiversity in this study. Transgenics were not one of them."

He and his colleagues based their findings on a two-year study of 81 commercial cotton fields in a region of Arizona that spans about 2,500 square miles (6,600 square kilometers). Much of the field and lab work was done by Manda G. Cattaneo as part of her master's research at UA. Cattaneo is now an extension entomologist at Texas A&M University in College Station.

The multidisciplinary team will publish their research in an upcoming issue of the Proceedings of the National Academy of Sciences. A complete list of authors is at the end of this release. The Environmental Protection Agency funded the research.

Bt cotton controls only one of Arizona's three major cotton pests. To control the other two pests, sweet potato whitefly (Bemisia tabaci) and the western tarnished plant bug (Lygus hesperus), growers use broad-spectrum insecticides and other types of insecticides known as insect growth regulators.

Carrière and his colleagues studied how Arizona farmers actually planted their crops and applied pesticides.

The researchers compared the yield and pesticide use for 40 fields of non-Bt cotton, 21 fields of Bt cotton and 20 fields of Bt cotton that was also herbicide-resistant.

In addition, each cotton field selected for the study was next to an uncultivated area. That allowed the researchers to compare ant and beetle biodiversity among the various cotton fields and the uncropped areas.

The team used Geographical Information Systems (GIS) and LANDSAT satellite imagery to map the fields and evaluate plant growth in the non-cultivated areas. Plant growth can affect the biodiversity of insects found in an area.

The researchers found that, per pesticide application, Bt cotton produced 9 percent more cotton/acre than non-Bt cotton. However, growers that planted Bt cotton used fewer applications of broad-spectrum insecticides.

As a result, growers ended up with similar yields/acre regardless of the type of cotton grown. Carrière suggests that yields were similar across cotton types because the additional insecticide applications on the non-Bt fields cut down on the damage from whiteflies and western tarnished plant bugs.

To see what factors affected insect biodiversity in the cotton fields, the researchers used a type of statistical analysis called path analysis. Factors that affected biodiversity included the sandiness of the soil, use of broad-spectrum insecticides and insect growth regulators, number of cotton seeds planted per acre, and the amount and types of plants in the adjacent uncultivated areas.

The researchers found that the type of cotton had no effect on how much insect biodiversity was in a particular field.

"Yield, pesticides and effects on non-target organisms -- we must look at those all together to assess the environmental impacts of transgenics," Carrière said. "The take-home message is that transgenic crops are very promising for reducing the impact of agriculture, but we need to study how they're integrated into the way we do agriculture. It depends on how the producers react to the technology."

He added, "It's a problem that is ecologically complex. We cannot say, 'Because it's good in Arizona that it will necessarily be good somewhere else.' We need to study many systems carefully before we can generalize."

Carrière's co-authors on the research article, "Farm-scale Evaluation of the Impacts of Transgenic Cotton on Biodiversity, Pesticide Use, and Yield," are Cattaneo of Texas A&M University in College Station; Christine Yafuso, Chris Schmidt, Carl Olson and Christa Ellers-Kirk of the department of entomology at The University of Arizona; Cho-ying Huang, Magfurar Rahman, Barron J. Orr and Stuart E. Marsh of the Arizona Remote Sensing Center at The University of Arizona; Larry Antilla of the Arizona Research and Protection Council in Phoenix; and Pierre Dutilleul of McGill University in St-Anne-de-Bellevue, Canada.

Related Web sites;
Yves Carrière,

UA Department of Entomology,



Biotech News - InvestBio Ventures Completes a $20 Million Investment in the Vaccine Company

Yahoo! Groups My Groups | biotech-news Main Page

InvestBio Ventures Completes a $20 Million Investment in the Vaccine Company to Further the Development of the PR1 Vaccine for Leukemia
    NEW YORK, May 5  -- InvestBio Ventures - The Vaccine Company, L.P., an InvestBio Ventures Partnership, announced today that it has completed a $20 million investment in The Vaccine Company (TVC). InvestPrivate, Inc. (member NASD, SIPC, SIA) acted as the placement agent for the offering.     The Vaccine Company was formed in July 2003 to commercialize the PR1 vaccine that is being developed at the M. D. Anderson Cancer Center at The University of Texas. The funding will help The Vaccine Company conduct a pivotal Phase III trial in acute myelogenous leukemia (AML). The company was recently granted a SPA (special protocol assessment) by the FDA.     Scott Mathis, CEO and Chairman of InvestBio stated, "We are extremely pleased with the progress of the PR1 Vaccine which was developed by Jeffrey Molldrem, MD of the M. D. Anderson Cancer Center. We are all very proud to help fund the clinical trials for the advancement of this vaccine. If the clinical trials are successful, this may well be a breakthrough in leukemia treatment and embodies our philosophy of Get Healthy, Get Wealthy by advancing important research for patients and investors alike."     Ron Garren, M.D., Chairman of The Vaccine Company stated, "We are excited about the clinical potential of the PR1 vaccine and look forward to initiating the Phase III trial in AML and further Phase II trials in related conditions." Gregory Thayer, CEO & President of TVC stated, "Our vaccine relies on mounting an immune response to a peptide/HLA-A2 complex presented on the surface of leukemia cells. We are very encouraged by results to date."     About InvestBio:     InvestBio, Inc. serves as a central resource for biotech investors seeking unbiased information and access to investment opportunities. InvestBio, Inc. identifies, selects, structures and manages biotechnology-related venture capital, private equity for qualified individual accredited investors.     InvestBio, Inc. is a holding of Diversified Biotech Holdings Corp. (DBHC), a diversified organization based in New York City that seeks to help investors and its customers capitalize on business and investment opportunities in the biotechnology sector.     About InvestPrivate:     InvestPrivate, Inc.  (member NASD, SIPC, SIA), founded in 1999 and headquartered in New York, is a boutique investment brokerage firm that specializes in the biotechnology sector, offering access to venture capital, private equity investments and publicly traded securities.     InvestPrivate, Inc. is a holding of Diversified Biotech Holdings Corp. (DBHC), a diversified organization that seeks to help investors and its customers capitalize on business and investment opportunities in the biotechnology sector.     1999 - 2006. InvestBio, Inc., a subsidiary of Diversified Biotech Holdings Corporation. This information is not intended for use without professional advice. 
    Important Notes:     The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. This press release may contain certain statements of a forward-looking nature relating to future events or future business performance. Any such statements that refer to the Company's estimated or anticipated future results or other non-historical facts are forward-looking and reflect the Company's current perspective of existing trends and information. These statements involve risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. The forward-looking statements speak only as of the date of this release. The Company undertakes no obligation to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise.